Section Navigation
Section Navigation
- Module 5 Overview
Prevention of HIV - 0%Lesson 1
Preventing Perinatal HIV TransmissionActivities- 0%Lesson 2
Preventing HIV Transmission in Persons with HIVActivities- 0%Lesson 3
Occupational Postexposure ProphylaxisLesson 3. Occupational Postexposure Prophylaxis
Learning Objective Performance Indicators
- Discuss risk for occupational acquisition of HIV with a needlestick injury
- State the rationale for using occupational HIV postexposure prophylaxis (PEP)
- Describe current indications for the use of occupational HIV PEP, including strategies for risk assessment following an occupational exposure
- Summarize recommended antiretroviral therapy regimens and duration of therapy for occupational HIV PEP
- List recommended clinical and laboratory monitoring following occupational exposure to HIV
About this Lesson
Learning Objective Performance Indicators
- Discuss risk for occupational acquisition of HIV with a needlestick injury
- State the rationale for using occupational HIV postexposure prophylaxis (PEP)
- Describe current indications for the use of occupational HIV PEP, including strategies for risk assessment following an occupational exposure
- Summarize recommended antiretroviral therapy regimens and duration of therapy for occupational HIV PEP
- List recommended clinical and laboratory monitoring following occupational exposure to HIV
Activities in this Lesson
- Quick ReferenceOccupational Postexposure Prophylaxis Core Concepts
- Introduction
- Rationale for HIV Occupational PEP
- Risk Assessment of the Occupational Exposure Event
- Recommended Initial Steps Following An Exposure Event
- Recommended Antiretroviral Regimens for Occupational HIV PEP
- Obtaining Expert Consultation for Occupational HIV PEP
- Baseline Evaluation for Health Care Personnel and Source Patient
- Follow-Up of Health Care Worker After Exposure Event
- Summary Points
Share by e-mail
Check
-On-
Learning
QuestionsThe Check-on-Learning Questions are short and topic related. They are meant to help you stay on track throughout each lesson and check your understanding of key concepts.You must be signed in to customize your interaction with these questions.
- 0%Lesson 2
Funded by
Health Resources and Services Administration (HRSA)
Created at
University of Washington
An AETC Program
Part of
IDEA Platform
CME provided byUniversity of Alabama Birmingham
CNE approved byOregon Nurses Association
Copyright © 2025 National HIV Curriculum
The Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS) provided financial support for this website. The award provided 100% of total costs and totaled $1,172,994. The contents are those of the author. They may not reflect the policies of HRSA, HHS, or the U.S. Government.
Since you've received 80% or better on this quiz, you may claim continuing education credit.
You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.
Current Version: nhivc-master-d52d2330-2025-09-05-201745
Bictegravir-Tenofovir alafenamide-Emtricitabine Biktarvy
Darunavir-Cobicistat-Tenofovir alafenamide-Emtricitabine Symtuza
Dolutegravir-Abacavir-Lamivudine Triumeq
Dolutegravir-Lamivudine Dovato
Dolutegravir-Rilpivirine Juluca
Doravirine-Tenofovir DF-Lamivudine Delstrigo
Efavirenz-Tenofovir DF-Emtricitabine Atripla
Elvitegravir-Cobicistat-Tenofovir alafenamide-Emtricitabine Genvoya
Elvitegravir-Cobicistat-Tenofovir DF-Emtricitabine Stribild
Rilpivirine-Tenofovir alafenamide-Emtricitabine Odefsey
Rilpivirine-Tenofovir DF-Emtricitabine Complera
Fostemsavir Rukobia
Ibalizumab Trogarzo
Maraviroc Selzentry
Dolutegravir Tivicay
Raltegravir Isentress
Tenofovir alafenamide-Emtricitabine Descovy
Tenofovir DF-Emtricitabine Truvada and Multiple Generics
Doravirine Pifeltro
Efavirenz Sustiva
Etravirine Intelence
Rilpivirine Edurant